Alivus Life Sciences Limited has announced the acquisition of a 76% stake in IQGenX Pharma Private Limited for a total consideration of INR 91.2 million. This strategic move is set to enhance Alivus’s capabilities in advanced formulation development and expand its integrated end-to-end platform. The acquisition is expected to close by the end of the current calendar year, bolstering Alivus’s global customer base and CDMO offerings.
Alivus Life Sciences Acquires Majority Stake in IQGenX
Mumbai, August 18, 2026 – Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, a prominent developer and manufacturer of high-value Active Pharmaceutical Ingredients (APIs), today announced a significant strategic acquisition. The company has secured a 76% stake in IQGenX Pharma Private Limited for a sum of INR 91.2 million.
Strategic Rationale and Enhanced Capabilities
IQGenX Pharma Private Limited, founded in October 2016, operates as a custom research organization specializing in formulation development for oral solids, sterile injectables, and ophthalmic solutions. Its expertise caters to highly regulated and semi-regulated markets including the US, EU, Latin America, and the Middle East. This acquisition enables Alivus to leverage its core API portfolio and expand into advanced formulation development, creating an integrated end-to-end platform. The combined entity will offer comprehensive scientific expertise across complex delivery formats, including oral solids, complex injectables, and ophthalmics.
Through the IQGenX platform, Alivus will extend its operational capabilities to include rigorous bioequivalence and stability studies. This will support comprehensive regulatory filings tailored for diverse global markets and significantly expand the company’s global customer base within the generic pharmaceutical segment. Additionally, Alivus aims to enhance its value proposition for global Contract Development and Manufacturing Organization (CDMO) customers, offering services from pre-formulation studies and prototype development to process optimisation, scale-up, clinical supplies, and full-scale commercial manufacturing.
Future Growth and Market Focus
Alivus plans to strategically leverage IQGenX’s specialized platform alongside its existing API portfolio, with a particular focus on the Oncology segment. This will facilitate the creation of a differentiated basket of niche assets, primed for strategic out-licensing. The company highlighted that these assets will be backed by validated, commercial-scale manufacturing capabilities.
The acquisition is subject to customary closing condition precedents and is anticipated to be completed by the end of the current calendar year.
About Alivus Life Sciences Ltd (ALIVUS)
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) is a leading developer and manufacturer of high-value, non-commoditized APIs in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management, and diabetes. The company is increasingly involved in providing CDMO services to multinational and specialty pharmaceutical companies. Alivus has a diversified portfolio of 181 molecules and serves customers across India, Europe, North America, Latin America, Japan, and the Rest of the World. Its four manufacturing facilities, located in Ankleshwar, Dahej, Mohol, and Kurkumbh, possess a total installed capacity of 1424 KL and are regularly inspected by global regulators like USFDA, PMDA (Japan), and EDQM (Europe). Alivus Life Sciences is listed on both the BSE and NSE.
Source: BSE
